

# Optimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

NCT07406217

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Calmy Alexandra
Enrollment	256 participants

## Key Eligibility Criteria

---

### Inclusion (28)

- Laboratory confirmed SARS-CoV-2 infection by real time RT-PCR or positive antigenic test (commercialized assay)
- Asymptomatic or mild to moderate COVID-19 (WHO progression scale  $\leq 5$ . Patients receiving oxygen therapy for reasons other than a pulmonary COVID-19 are eligible).
- $\geq 16$  years of age;
- Immunocompromised as defined by  $\geq 1$  risk factors for severe COVID-19 as assessed by the Federal Office of Public Health (FOPH) list (criteria 5: diseases/treatments leading to immune suppression) or other immunosuppression criteria such as:
- Severe immunosuppression (e.g., human immunodeficiency virus (HIV) infection with CD4 + T cell count  $< 350 / \mu\text{l}$ )
- ... and 23 more (see full listing online)

### Exclusion (10)

- SARS-CoV-2 PCR  $\leq 30$  CT at screening
- Hypersensitivity to study drugs (active substance(s) or excipients)
- Body weight  $< 40$  kg
- AST (Aspartate transaminase) and/or alanine transaminase (ALT)  $> 5$  times the upper limit
- Cirrhosis Child-Pugh score C
- ... and 5 more (see full listing online)

## Locations (4 total)

---

Basel University Hospital, Basel, Basel, Switzerland  
Hôpitaux Universitaires de Genève, Geneva, Canton of Geneva, Switzerland  
CHUV, Lausanne, Canton of Vaud, Switzerland  
... and 1 more locations